BACKGROUND: The safety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally human immunodeficiency virus type 1 (HIV-1)-infected children, adolescents, and young adults are unknown. METHODS: Two 30-μg doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin) were administered 21-28 days apart to perinatally HIV-1-infected children, adolescents, and young adults. Antibodies were measured by hemagglutination inhibition (HAI) assay at baseline, 21-28 days after first vaccination, 7-13 days after the second vaccination, and 7 months after the first vaccination. RESULTS: Among the 155 participants, 54 were aged 4-8 years, 51 were aged 9-17 years, and 50 were aged 18-24 years. After 2 doses of Fluvirin, seroresponse (≥ 4-fold rise in HAI titers) was demonstrated in 79.6%, 84.8%, and 83% of participants in the aforementioned age groups, respectively, and seroprotection (HAI titers ≥ 40) was shown in 79.6%, 82.6%, and 85.1%, respectively. Of those lacking seroresponse (n = 43) or seroprotection (n = 37) after the first vaccination, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccination. Among participants who lacked seroprotection at entry, a "complete response" (both seroresponse and seroprotection) after first vaccination was associated with higher baseline log(10) HAI titer and non-Hispanic ethnicity. No serious vaccine-related events occurred. CONCLUSION: Two doses of double-strength pH1N1 vaccine are safe and immunogenic and may provide improved protection against influenza in perinatally HIV-1-infected children and youth. CLINICAL TRIALS REGISTRATION: NCT00992836.
BACKGROUND: The safety and immunogenicity of high-dose pandemic H1N1 (pH1N1) vaccination in perinatally human immunodeficiency virus type 1 (HIV-1)-infectedchildren, adolescents, and young adults are unknown. METHODS: Two 30-μg doses of 2009 Novartis pH1N1 monovalent vaccine (Fluvirin) were administered 21-28 days apart to perinatally HIV-1-infectedchildren, adolescents, and young adults. Antibodies were measured by hemagglutination inhibition (HAI) assay at baseline, 21-28 days after first vaccination, 7-13 days after the second vaccination, and 7 months after the first vaccination. RESULTS: Among the 155 participants, 54 were aged 4-8 years, 51 were aged 9-17 years, and 50 were aged 18-24 years. After 2 doses of Fluvirin, seroresponse (≥ 4-fold rise in HAI titers) was demonstrated in 79.6%, 84.8%, and 83% of participants in the aforementioned age groups, respectively, and seroprotection (HAI titers ≥ 40) was shown in 79.6%, 82.6%, and 85.1%, respectively. Of those lacking seroresponse (n = 43) or seroprotection (n = 37) after the first vaccination, 46.5% and 40.5% achieved seroresponse or seroprotection, respectively, after the second vaccination. Among participants who lacked seroprotection at entry, a "complete response" (both seroresponse and seroprotection) after first vaccination was associated with higher baseline log(10) HAI titer and non-Hispanic ethnicity. No serious vaccine-related events occurred. CONCLUSION: Two doses of double-strength pH1N1 vaccine are safe and immunogenic and may provide improved protection against influenza in perinatally HIV-1-infectedchildren and youth. CLINICAL TRIALS REGISTRATION: NCT00992836.
Authors: Claudia Vellozzi; Karen R Broder; Penina Haber; Alice Guh; Michael Nguyen; Maria Cano; Paige Lewis; Michael M McNeil; Marthe Bryant; James Singleton; David Martin; Frank DeStefano Journal: Vaccine Date: 2010-09-16 Impact factor: 3.641
Authors: Pablo Tebas; Ian Frank; Mark Lewis; Joseph Quinn; Larisa Zifchak; Aleshia Thomas; Thomas Kenney; Rosemary Kappes; Wayne Wagner; Kathy Maffei; Kathleen Sullivan Journal: AIDS Date: 2010-09-10 Impact factor: 4.177
Authors: Jen Kok; Katherine Tudo; Christopher C Blyth; Hong Foo; Linda Hueston; Dominic E Dwyer Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Markus Bickel; Nils von Hentig; Imke Wieters; Pavel Khaykin; Gabi Nisius; Annette Haberl; Christoph Stephan; Eva Herrmann; Hans W Doerr; Hans Reinhard Brodt; Regina Allwinn Journal: Clin Infect Dis Date: 2011-01-01 Impact factor: 9.079
Authors: Rulin C Hechter; Lei Qian; Sara Y Tartof; Lina S Sy; Nicola P Klein; Eric Weintraub; Cheryl Mercado; Allison Naleway; Huong Q McLean; Steven J Jacobsen Journal: Vaccine Date: 2019-05-04 Impact factor: 3.641
Authors: Robert F Pass; Sharon Nachman; Patricia M Flynn; Petronella Muresan; Terence Fenton; Coleen K Cunningham; William Borkowsky; James B McAuley; Stephen A Spector; Elizabeth Petzold; Wende Levy; George K Siberry; Ed Handelsman; L Jill Utech; Adriana Weinberg Journal: J Pediatric Infect Dis Soc Date: 2013-07-17 Impact factor: 3.164
Authors: Adriana Weinberg; Petronella Muresan; Terence Fenton; Kelly Richardson; Teresa Dominguez; Anthony Bloom; Elizabeth Petzold; Patricia Anthony; Coleen K Cunningham; Stephen A Spector; Sharon Nachman; George K Siberry; Edward Handelsman; Patricia M Flynn Journal: Hum Vaccin Immunother Date: 2013-01-31 Impact factor: 3.452
Authors: Donna J Curtis; Petronella Muresan; Sharon Nachman; Terence Fenton; Kelly M Richardson; Teresa Dominguez; Patricia M Flynn; Stephen A Spector; Coleen K Cunningham; Anthony Bloom; Adriana Weinberg Journal: PLoS One Date: 2015-03-18 Impact factor: 3.240
Authors: Adriana Weinberg; Petronella Muresan; Kelly M Richardson; Terence Fenton; Teresa Dominguez; Anthony Bloom; D Heather Watts; Mark J Abzug; Sharon A Nachman; Myron J Levin Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240
Authors: Adriana Weinberg; Petronella Muresan; Kelly Richardson; Terence Fenton; Teresa Dominguez; Anthony Bloom; D Heather Watts; Mark J Abzug; Sharon A Nachman; Myron J Levin Journal: AIDS Res Hum Retroviruses Date: 2015-08-31 Impact factor: 2.205
Authors: Adriana Weinberg; Donna Curtis; Mariangeli Freitas Ning; David Jeremy Claypool; Emilie Jalbert; Julie Patterson; Daniel N Frank; Diana Ir; Carl Armon Journal: Front Immunol Date: 2016-04-15 Impact factor: 7.561